Sensitive skin
Conditions
Interventions
Experimental group:Use test cosmetics
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
19 Years to 57 Years
Inclusion criteria
Inclusion criteria: 1. Volunteer to participate in this study and had signed the informed consent to use the product; 2. Subjects have reasonable expectations and are able to understand and comply with the instructions and all visit schedules; 3. Male and female aged between 18 and 65; 4. Subjects are willing not to undergo any other facial plastic or cosmetic surgery during the study period; 5. Sensitive skin combined with acne: patients with clinical diagnosis of Pillsbury grade II, and lactic acid stimulation test score >= 3 or capsaicin test score >= 3; 6. Sensitive skin combined with erythematous rosacea clinical symptoms and signs included mid-face paroxysmal flushing or persistent erythema with or without a few papules, lactic acid stimulation test score >= 3 or capsaicin test score >= 3; 7. Sensitive skin: lactic acid stimulation test score >= 3; or >= 3 on capsaicin test. The first four of inclusion criteria are necessary, and the last three criteria meet one of them.
Exclusion criteria
Exclusion criteria: 1. No informed consent is filled in; 2. Allergic to the known components of the product (the main components of the product are prinsepia utilis rogle oil, ceramide 3, cholesterin, purslane extract, Physalis calyx extract or other known components); 3. Pregnant or planning to become pregnant during the study period, or breastfeeding; 4. Currently suffering from other facial erythematosus diseases, such as lupus erythematosus, photosensitive dermatitis, seborrheic dermatitis, corticosteroid addictive dermatitis and contact dermatitis; 5. With severe or progressive disease, according to the researcher's judgement, the subjects took the inappropriate risk participating in the clinical trial (i.e. cancer, or cancer symptoms, immunocompromised patients, uncontrolled diabetes, epilepsy, serious cardio-cerebrovascular disease) (i.e. stroke, idiopathic aortic stenosis and aneurysm, hypertrophic obstructive cardiomyopathy, ischemic heart disease, tachyarrhythmia, severe heart failure [NYHA classification III-IV], etc.); 6. Have an active autoimmune disease (e.g. inflammatory bowel disease) or a history of it, or an active connective tissue disease (rheumatoid arthritis, scleroderma, and systemic lupus erythematosus); 7. Have received chemotherapy, immunosuppressant, immunoregulatory therapy (e.g. monoclonal antibodies), and systemic corticosteroids (inhaled corticosteroids permitted) within 3 months; 8. Subjects participating in other clinical trials or in the screening period of a clinical trial within 30 days; 9. Patients who have taken oral steroids, antihistamines, antibiotics, viaminati, topical hormones and unknown ingredients in the past one month; 10. Staff members or close relatives of staff (e.g. parents, children, siblings or spouses) of departments in the research center, and employees or close relatives of employees of the sponsor or CRO company; 11. Other conditions deemed inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal water loss;Erythema index;Subject self-assessment;Doctor assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stratum corneum hydration;pH value;Skin oil content;Facial photography; | — |
Countries
China
Contacts
Public ContactLi Li
West China Hospital, Sichuan University
Outcome results
None listed